about
Decreased variability of the 6-minute walk test by heart rate correction in patients with neuromuscular diseaseMutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy.Axial myopathy: an overlooked feature of muscle diseases.Has basic research contributed to chronic pain treatment?Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance studyClinical and genetic spectrum in limb-girdle muscular dystrophy type 2EAerobic Training in Patients with Congenital Myopathy.Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or 'classical' congenital myopathy.Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years.Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark.Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome.Prevalence and phenotypes of congenital myopathy due to α-actin 1 gene mutations.Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype.The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts.Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy.A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy.Frequency and phenotype of patients carrying TPM2 and TPM3 gene mutations in a cohort of 94 patients with congenital myopathy.High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: a cross-sectional study.Congenital titinopathy: Comprehensive characterisation and pathogenic insights.Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases.A PET activation study of brush-evoked allodynia in patients with nerve injury pain.Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an older patient.Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome.Severe axial myopathy in McArdle disease.Reliability of the 2- and 6-minute walk tests in neuromuscular diseasesProgression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up studyEndocrine function over time in patients with myotonic dystrophy type 1Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophyOcular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophyResponseBecker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2Differential recruitment of endogenous pain inhibitory systems in neuropathic pain patientsRepetitive intradermal capsaicin: differential effect on pain and areas of allodynia and punctate hyperalgesia
P50
Q28542539-DBCF910A-9C3B-4052-BBA4-2619FCBF63FBQ30413900-773430BC-F81A-4DB5-BD4A-B9FAF8199166Q31032086-9F02E63F-60DB-4B7C-A0EC-1A9BC11AA7FAQ34421461-9E1F47C0-2F88-4EC0-852A-1C1D3B8849CAQ35576188-301EE8CA-6712-4D79-B0BE-D80E1DB1E3D4Q35582438-ED6EAD09-3EF1-430A-91FC-94D83D6842A4Q35890267-6EA587F9-F30D-4B1B-BB87-02AA6581B34BQ36615476-3912E35C-CBC4-484A-81DA-154998CEABE2Q37610554-53D2EC7D-A9D1-4F99-B45E-50CA1DB3EBECQ37716090-12A5DAAA-7048-47A3-B8A9-3477BF6036ACQ38178549-9F16FD86-7AB7-493D-82B8-709E6C00C3DFQ41588609-EFE0C29A-E4ED-4683-A39F-58866E9EAE2EQ41855877-96266C70-3D73-4D3E-B286-17822471A322Q48011157-E2607497-43B1-42D7-B126-1A87F95BE84BQ48226149-1184136B-61CB-4B52-A3CA-1F8E4C7D418BQ48590768-1085A2A9-4651-40E6-B59A-1512C819CA04Q48695686-DC435365-80F8-4BD6-92B2-BC81498595DBQ51162545-C962D6D1-7CDB-4098-80A9-940FA4491B9BQ51743589-496B5CAA-CC03-4A5D-8290-5D93FB88EAC7Q52565198-D31BC5D2-5815-420A-8268-9B7D4A980E5EQ53220865-51559F08-0545-4E19-B08C-F9628A3D1FD7Q53559144-8D5F9538-AEE8-4036-9D01-7461BA49F96FQ53634475-648B5EF4-DB78-434C-9459-95A7D9697D8AQ54116685-E572AC58-5A1F-45E3-A017-A511B44B1E89Q54397896-085C153A-45C4-4E93-A0DE-EB59513F5CF1Q60772242-A9F4BA27-5F11-4B9E-83A1-52B756D792A4Q60772288-AAD4A0CE-45D3-4CA3-B704-4B585E9224D8Q60772295-0ED3C2CB-BD0D-446C-92D0-E461109BB9CCQ60772304-F2DEE4E9-9604-4E6D-AFBE-7421E69D476BQ60772312-4C5854B4-9F5A-48CD-B6AC-EC8E9835EAC7Q60772354-2FC83692-4428-49CA-9547-6C3DD8DEDEF2Q60772362-0CCD35B8-67D1-4347-A5AD-38DBD18C2E09Q60772388-86F85C59-B099-476F-904B-F6A4DFB3D997Q60772400-0C0DFC46-CA58-4DA9-A07A-A54A475B1F02
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nanna Witting
@ast
Nanna Witting
@en
Nanna Witting
@es
Nanna Witting
@nl
Nanna Witting
@sl
type
label
Nanna Witting
@ast
Nanna Witting
@en
Nanna Witting
@es
Nanna Witting
@nl
Nanna Witting
@sl
prefLabel
Nanna Witting
@ast
Nanna Witting
@en
Nanna Witting
@es
Nanna Witting
@nl
Nanna Witting
@sl
P106
P108
P21
P31
P496
0000-0002-0664-0709